Researchers have discovered a new biomarker for Parkinson’s that could be used to identify people at risk of the disease and profoundly change the way it is treated.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.